AstraZeneca says amyloidosis drug fails Phase 3 trials, but claims potential in undisclosed subgroup
Last year, AstraZeneca predicted that its drug for the rare disease light chain amyloidosis could have peak revenue of up to $3 billion. But after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
